IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma
BLOOD, vol.119, no.8, pp.1901-1903, 2012 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 119 Issue: 8
- Publication Date: 2012
- Doi Number: 10.1182/blood-2011-11-391748
- Journal Name: BLOOD
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.1901-1903
- Open Archive Collection: AVESIS Open Access Collection
- Dokuz Eylül University Affiliated: No
Abstract
Mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) occur in most grade 2 and 3 gliomas, secondary glioblastomas, and a subset of acute myelogenous leukemias but have not been detected in other tumor types. The mutations occur at specific arginine residues and result in the acquisition of a novel enzymatic activity that converts 2-oxoglutarate to D-2-hydroxyglutarate. This study reports IDH1 and IDH2 genotyping results from a set of lymphomas, which included a large set of peripheral T-cell lymphomas. IDH2 mutations were identified in approximately 20% of angioimmunoblastic T-cell lymphomas (AITLs), but not in other peripheral T-cell lymphoma entities. These results were confirmed in an independent set of AITL patients, where the IDH2 mutation rate was approximately 45%. This is the second common genetic lesion identified in AITL after TET2 and extends the number of neoplastic diseases where IDH1 and IDH2 mutations may play a role. (Blood. 2012;119(8):1901-1903)